Dosing and Safety

Cross-source consensus on Dosing and Safety from 1 sources and 8 claims.

1 sources · 8 claims

Dosage & preparation

Studied human doses are described as escalating from 500 mg to 1 g, with 2 g showing exposure similar to 1 g. — Urolithin A, Mitochondria, Performance, and Aging
Long-term lifelong safety and use in all populations remain incompletely established. — Urolithin A, Mitochondria, Performance, and Aging
Alternate-day dosing is discussed as plausible, but not established by human clinical evidence. — Urolithin A, Mitochondria, Performance, and Aging
The source reports no observed side effects in trials spanning participants aged 19 to 89. — Urolithin A, Mitochondria, Performance, and Aging
Powders, soft gels, and protein-containing formats are said to have similar bioavailability. — Urolithin A, Mitochondria, Performance, and Aging
Available evidence is presented as showing similar absorption across tested forms and meal conditions. — Urolithin A, Mitochondria, Performance, and Aging
A roughly one-day half-life is used to support once-daily dosing in studied protocols. — Urolithin A, Mitochondria, Performance, and Aging
Drug-interaction concerns are described as low in older adults taking multiple medications, with no major interaction concerns reported. — Urolithin A, Mitochondria, Performance, and Aging